Alcoholic Hepatitis (AH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Alcohol stands as one of the most commonly consumed substances globally, socially embraced despite its harmful effects on the liver. Excessive alcohol intake results in various health issues, leading to substantial healthcare expenses related to alcohol-induced disorders. Among these, Alcoholic Hepatitis (AH) emerges as a critical and potentially life-threatening condition. This acute liver disease, often dubbed "acute alcoholic hepatitis," signifies the most severe form within the spectrum of alcoholic liver diseases. The clinical manifestation of AH varies widely, spanning from mild to severe cases. While clinical jaundice appears in 40%-60% of instances, nearly all AH patients exhibit hyperbilirubinemia, a hallmark of the disease. Additional symptoms include right upper quadrant pain, fever, increased heart rate, and an enlarged, tender liver. AH frequently intertwines with systemic inflammatory response syndrome (SIRS) and moderate fever, sometimes with underlying infections. Despite this, around 35% of heavy drinkers show signs of alcoholic steatohepatitis in liver biopsies without necessarily displaying the complete clinical syndrome. Diagnostic criteria for AH lack standardization or international consensus. However, a combination of mildly elevated liver enzymes, notably high serum bilirubin levels exceeding 80 μmol per liter, an increased INR, neutrophilia, and a history of heavy alcohol consumption strongly suggests AH. Unfortunately, there are currently no FDA-approved medications specifically for treating alcoholic hepatitis, leaving a gap in the pharmacotherapy options for alcoholic liver disease (ALD).

·       The overall prevalence of Alcohol-Related Liver Disease (ARLD) in the general population is approximately 4.8%, with fluctuations ranging from 1.0% to 16.1%. Notably, prevalence tends to be higher among males compared to females.

 

Thelansis’s “Alcoholic Hepatitis (AH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alcoholic Hepatitis (AH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Alcoholic Hepatitis (AH) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Alcoholic Hepatitis (AH) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Alcoholic Hepatitis (AH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Alcoholic Hepatitis (AH), Alcoholic Hepatitis (AH) market outlook, Alcoholic Hepatitis (AH) competitive landscape, Alcoholic Hepatitis (AH) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)